A prospective randomized controlled study of oral tranxenamic acid for the prevention of postinflammatory hyperpigmentation after Q-switched 532 Nd:YAG laser for solar lentigines

        Background: Solar lentigines are benign pigmented disorder caused by long term sun exposure. Q-switched 532-nm Nd-Yag laser is known as an effective treatment option for solar lentigines. However, the high incidence of postinflammatory hyperpigmentation is concerning especially in darker skin types. Tranexamic acid, which is plasmin inhibitor, is used to treat melasma by decreasing melanogenesis. In addition, it is also used for postinflammatory hyperpigmentation prevention.
        To read this article in full you will need to make a payment
        AAD Member Login
        AAD Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features
        Already a print subscriber? Claim online access
        Already an online subscriber? Sign in
        Institutional Access: Sign in to ScienceDirect